![](https://endpts.com/wp-content/uploads/2022/08/Berndt-Modig-Pharvaris-tile1.jpg)
Berndt Modig, Pharvaris CEO
Pharvaris hits a snag with hereditary angioedema pill as FDA places hold on trials
Swiss biotech Pharvaris announced Monday that the FDA has placed a hold on the clinical trials for its oral drug PHA121 which aims at treating …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.